For instance, trials for non-small cell lung cancer (NSCLC) focus on biomarkers like Programmed Death-Ligand 1 (PD-L1) and Epidermal Growth Factor Receptor (EGFR) mutations, with promising results leading to the approval of several targeted therapies (10). This evidence concerns the gene CD274 and non-small cell lung carcinoma.